European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Glaxosmithkline Intellectual Property Management Ltd., Stevenage

Watch
Glaxosmithkline Intellectual Property Management Ltd.

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Glaxosmithkline Intellectual Property Management Ltd.

Identification

Chp
Companies House 07739397
Lei
5493003QN1IPYBD6WC49

Address

Gunnels Wood Road, Gsk Medicines Research Centre, Stevenage SG1 2NY, United Kingdom
980 Great West Road Brentford Middlesex, United Kingdom
Gsk Medicines Research Centre Gunnels Wood Road Stevenage, United Kingdom

Corporate purpose

82.99
Other business support service activities n.e.c.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Total assets

For this company, Total assets numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
5Director
2Director
1Secretary
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Portfolio and Investments
One known active shareholding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Earnings CAGR
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Taxes
Tax ratio
Cash on hand
Receivables
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

20 Aug 2026 also 28/09/2016, 24/09/2015, 16/08/2014, 06/09/2013, 29/08/2012
Full accounts made up to 2025-12-31
16 Apr 2026 also 30/07/2025, 15/08/2024, 10/08/2023, 18/08/2022, 10/08/2021, 19/08/2020, 19/08/2019, 22/08/2018, 11/08/2017
Confirmation statement made with no updates
15 Aug 2025
Annual report for the year ending 31/12/2024
15 Jul 2025
Director: Anna M. H. Fent
9 Jul 2025
No longer Director: Jemma-L. Reynolds
27 Sept 2024
Director: C. Barcelo Igles
20 Sept 2024
Director's details changed for Mrs Demet Gurunlu Russ
17 Sept 2024
Director's details changed for Mr Graham Paul Rivers · Director's details changed for Mrs Jemma-Louise Reynolds …
11 Sept 2024 also 21/08/2013
Director's details changed for The Wellcome Foundation Limited
14 Aug 2024
Annual report for the year ending 31/12/2023
14 Aug 2024
Patent: Method for controlling antibody glycosylation profile
31 Jul 2024
No longer Director: Gregory M. Reinaud
18 Jul 2024
Address
11 Jul 2024
Appointment of Mrs Demet Gurunlu Russ as a director
5 Jul 2024
No longer Director: Jill Dawn Anderson
17 May 2024
Patent: New use of anti-Blys antibodies
15 Apr 2024
Director: Jemma-L. Reynolds
2 Feb 2024
Director: Gregory M. Reinaud
20 Sept 2023
No longer Director: Ziba Shamsi
16 Aug 2023
Annual report for the year ending 31/12/2022
16 Aug 2023
Companies House - Filing
2 Aug 2023
Director: Graham Paul Rivers
20 Jul 2023
No longer Director: James R. Wheatcroft
9 Jun 2023
Address
6 Jun 2023
Address
3 Mar 2023
Director: Jill Dawn Anderson
2 Mar 2023
No longer Director: Jerome Andries
3 Nov 2022
Director: Ziba Shamsi
2 Nov 2022
Termination of appointment of Kate Sophie Priestman as a director
15 Aug 2022
Annual report for the year ending 31/12/2021
20 Jul 2022
Patent: Belimumab Formulation
15 Jun 2022
Patent: Anti-Baff Antibodies for USE in a Method of Treatment of Long Covid and/or Post-Acute Sequelae Sars-COV-2 Infection (Pasc)
29 Sept 2021
Annual report for the year ending 31/12/2020
30 Jun 2021
Patent: Healthcare Product Package
6 Nov 2020
Annual report for the year ending 31/12/2019
Year 2019 in Euipods
12 registered designs
24 Sept 2019
Annual report for the year ending 31/12/2018
3 Sept 2019
Director: James R. Wheatcroft
9 May 2019
No longer Director: Simon Paul Dingemans
15 Jan 2019
No longer Secretary (1) · Secretary: Edinburgh Pharmaceutical Industries Ltd
6 Oct 2018
Annual report for the year ending 31/12/2017
29 Jan 2018
Director's details changed for Mr Jerome Charles Maurice Andries
Year 2018 in Epobase
4 European patent filings: Compounds …
17 Nov 2017
Director: Jerome Andries
16 Nov 2017
No longer Director: Luigi F. la Corte
27 Sept 2017
Annual report for the year ending 31/12/2016
5 Sept 2017
Patent: Transduced Cell Cryoformulation
7 Jan 2017
Appointment of Kate Sophie Priestman as a director
2 Nov 2016
No longer Director (1)
21 Sept 2016
Patent: Dosing schedule for the combination of anti-CD20 and anti-BlyS antibodies
17 Aug 2016
Confirmation statement made with updates
8 Feb 2016
No longer Director (1)
26 Aug 2015
Capital: £101.00
Year 2015 in Epobase
4 European patent filings: 1,2,3,5-Tetrahydroimidazo[1,2-C]Pyrimidine Derivatives Useful in the Treatment of Diseases and Disorders Mediated by LP-PLA2 …
15 May 2015
Director: Luigi F. la Corte
Year 2014 in Euipods
12 registered designs
14 Aug 2014
Capital: £101.00
27 May 2014
Director: Simon Paul Dingemans
22 Aug 2013
Capital: £101.00
16 Aug 2013
Director: Adam Walker
31 Jan 2013
Statement of capital following an allotment of shares
6 Sept 2012
Annual return made up to 2012-08-12 with full list of shareholders
5 Mar 2012
Previous accounting period shortened from 2012-08-31 to 2011-12-31
12 Aug 2011
Reg­is­tra­tion: 12/08/2011 · Director (1) · Secretary (1) · Director: Edinburgh Pharmaceutical Industries Ltd., The Wellcome Foundation Ltd
There are no publications matching your search.

Mentions

6 Jul 2024 in Psc
Companies House - Persons with Significant Control
31 Jul 2023 in Ler
Direct parent: Glaxosmithkline Intellectual Property Development Ltd
31 Jul 2023 in Ler
Direct parent
31 Jul 2023 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.